PMCB — PharmaCyte Biotech Inc
NASDAQ · Healthcare · Biotechnology
$0.49
+$0.00 (+0.39%)
PharmaCyte Biotech Inc (PMCB) is a biotechnology company listed on NASDAQ. It is led by Joshua N. Silverman, based in 3960 Howard Hughes Parkway, Las Vegas, NV, United States, 89169, with about 2 employees. PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. It also develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; license agreements with SG Austria Pte. Ltd.; and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
Latest reported PMCB revenue for 2025-07-31 was $0. Net income was -$8.4M. PMCB currently screens at market cap $8.6M.
Use this PMCB page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the PMCB quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the PMCB SEC filings page. Lician reads the product cache first so this HTML stays unique to PharmaCyte Biotech Inc even when a live quote feed is slow.
About PharmaCyte Biotech Inc
PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. It also develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; license agreements with SG Austria Pte. Ltd.; and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
PMCB Key Statistics
Market Cap
$8.59M
Volume
62,973
Previous Close
$0.53
Day Range
$0.51 – $0.54
P/B Ratio
0.23
EPS
$3.19
Revenue
$0.00
Net Income
$30.66M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
2
PMCB Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | $30.66M | $333.76K | -$4.32M | -$4.24M |
| EPS (Diluted) | $3.19 | -$1.80 | -$0.22 | -$0.27 |
Total Assets
$55.17M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$15.17M
Operating Cash Flow
-$2.98M
Free Cash Flow
$0.00
PharmaCyte Biotech Inc Company Information
- CEO. President & Executive Chairman
- Joshua N. Silverman
- Headquarters
- 3960 Howard Hughes Parkway, Las Vegas, NV, United States, 89169
- Website
- pharmacyte.com
- Phone
- 917 595 2850
- IPO / Founded
- 2010-09-17
- Sector
- Healthcare
- Industry
- Biotechnology